For the Inventor, By the Inventor

Enter assignee name

Cantargia Ab

USPTO Granted Patents = 18

EPO Patents = 8

Forward Citations = 88

Loading Chart...

Loading Chart...

17 inventors (with patents filed for the assignee):

Thoas Fioretos (14 out of 14 patents)

Marcus Järås (14 out of 14 patents)

Kjell Sjöström (10 out of 15 patents)

4. Karin Von Wachenfeldt (10 out of 16 patents)

5. Cecilia Ann-Christin Malmborg Hager (7 out of 10 patents)

6. Helena Ågerstam (7 out of 7 patents)

7. Agneta Svedberg (7 out of 9 patents)

8. David Liberg (3 out of 8 patents)

9. Camilla Rydberg Millrud (2 out of 2 patents)

10. Gabriel Svensson Birkedal (2 out of 2 patents)

11. Sara Rattik (2 out of 2 patents)

12. Ying Ping Jiang (1 out of 1 patent)

13. Leonard G Presta (1 out of 1 patent)

14. Göran Forsberg (1 out of 7 patents)

15. Caitríona Grönberg (1 out of 1 patent)

18 patents: Sort by Forward Citations

1. 12398213 - Methods of treating IL1RAP associated cancers with anti human interleukin-1 receptor accessory protein (IL1 RAP) antibodies (2025-08-26),

2. 12209131 - Anti-IL1RAP antibody compositions (2025-01-28),

3. 12043666 - Anti-IL1RAP antibody (2024-07-23),

4. 11773174 - Anti-IL1RAP antibodies and their use for treating humans (2023-10-03),

5. 11479610 - Anti-IL1RAP antibody (2022-10-25),

6. 11359025 - Anti-IL1-RAP antibodies (2022-06-14),

7. 11236172 - Methods of producing an IL-1 RAP antibodies (2022-02-01),

8. 10995144 - Methods of detecting a solid tumor with anti-IL1RAP antibodies (2021-05-04),

9. 10878703 - Method of treatment of leukemia with anti-IL1RAP antibodies (2020-12-29),

10. 10752692 - Anti human interleukin-1 receptor accessory protein (IL1 RAP) antibodies and uses thereof (2020-08-25),

11. 10562971 - Method of detection of IL1RAP on cells expressing the protein (2020-02-18),

12. 10287357 - Methods of treating cancer using anti human interleukin-1 receptor accessory protein (IL1 RAP) antibodies (2019-05-14),

13. 10100119 - Anti-human interleukin-1 receptor accessory protein antibody and its use for treating cancer (2018-10-16),

14. 10005842 - Method of treatment for leukemia using an anti-IL1RAP antibody (2018-06-26),

15. 10005841 - Method of treating a solid tumor with IL1RAP antibodies (2018-06-26),

Cantargia AB is a biotechnology company that develops antibody-based cancer treatments. The company focuses on targeting the interleukin 1 receptor accessory protein (IL1RAP) to combat cancer. Cantargia's innovative approach aims to improve the efficacy and safety of cancer therapies. Through extensive research and development, Cantargia strives to revolutionize cancer treatment and enhance patient outcomes.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

18 Patents

#23 in Lund

#340 in Sweden

#33,187 in the World

Cantargia Ab

Forward Citations = 88

17 inventors:

Thoas Fioretos (14 out of 14 patents)

Marcus Järås (14 out of 14 patents)

Kjell Sjöström (10 out of 15 patents)

4. Karin Von Wachenfeldt (10 out of 16 patents)

5. Cecilia Ann-Christin Malmborg Hager (7 out of 10 patents)

Please report any incorrect information to support@idiyas.com

Loading…